Association between the baseline immune response signatures for cytomegalovirus/Epstein-Barr virus (CMV/EBV) and media alone and clinical improvement at 21 to 24 weeks among 71 patients with early rheumatoid arthritis. (A- C) Shown are box plots for the distributions of the CMV/EBV PCA-1, CMV/EBV PCA-2, and media alone PCA-2 scores, respectively, comparing responders and non-responders to initial disease-modifying treatment. Values were scaled from 0 to 100. (D- I) Shown are box plots representing the distributions of individual cytokines in the CMV/EBV PCA-1 signature in pg/mL. Clinical response was defined by a decrease in the DAS28 ≥1.2 from baseline to follow up. PCA, principal components analysis; DAS28, disease activity score in 28 joints.